Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovant Gene Therapies Ltd.

Division of Roivant Sciences Inc.
www.axovant.com

Latest From Axovant Gene Therapies Ltd.

Parkinson’s Disease: Novel Science And Collaborations Fuel Progress

Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.

BioPharmaceutical Neurology

Venture Funding Deals: Tenaya's $92m, Nuvation's $275m Lead October Rounds

Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.

Deals Financing

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

Business Strategies Commercial

David Hung Launches Start-Up Nuvation With Old Medivation Team And $275m

The former Medivation CEO, after a brief detour heading up Axovant, is returning to oncology, but the new company is keeping details about the seven cancer drug programs in its pipeline under wraps.

Financing Leadership
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Axovant Sciences Ltd.
  • Roivant Neurosciences Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Roivant Sciences Inc.
  • Senior Management
  • Pavan Cheruvu, MD, CEO
    David Nassif, CFO
    Fraser Wright, PhD, CTO
    Shankar Ramaswamy, MD, Chief Business Officer
    Gavin Corcoran, MD, EVP, R&D
    Ilise Lombardo, MD, CMO
    Paul Korner, MD, SVP, Clin. Dev.
  • Contact Info
  • Axovant Gene Therapies Ltd.
    Phone: 1-295-5950
    20-22 Bedford Row
    London, X0 WC1R 4J
    UK
UsernamePublicRestriction

Register